{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:28:03Z","timestamp":1784950083307,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Benjamin Crespy"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jcv.2017.12.011","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T12:49:31Z","timestamp":1514551771000},"page":"38-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation"],"prefix":"10.1016","volume":"99-100","author":[{"given":"Johan","family":"Noble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gatault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Sautenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Gaudy-Graffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Beby-Defaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Thierry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Essig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Halimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Alain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Buchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2017.12.011_bib0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1432-2277.2000.tb01019.x","article-title":"Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses","volume":"13","author":"Toupance","year":"2000","journal-title":"Transpl. Int."},{"key":"10.1016\/j.jcv.2017.12.011_bib0010","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1681\/ASN.2013060663","article-title":"Polyclonal antithymocyte globulin and cardiovascular disease in kidney transplant recipients","volume":"25","author":"Ducloux","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jcv.2017.12.011_bib0015","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1681\/ASN.2005050463","article-title":"Chronic renal allograft dysfunction","volume":"16","author":"Chapman","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jcv.2017.12.011_bib0020","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/0886022X.2016.1214147","article-title":"Active CMV and EBV infections in renal transplant recipients with unexplained fever and elevated serum creatinine","volume":"38","author":"Hasannia","year":"2016","journal-title":"Ren. Fail."},{"key":"10.1016\/j.jcv.2017.12.011_bib0025","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1128\/JVI.78.9.4498-4507.2004","article-title":"Activation of the NF-kappaB pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter","volume":"78","author":"DeMeritt","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.jcv.2017.12.011_bib0030","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1128\/JVI.75.10.4814-4822.2001","article-title":"Allogeneic transplantation induces expression of cytomegalovirus immediate-early genes in vivo: a model for reactivation from latency","volume":"75","author":"Hummel","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.jcv.2017.12.011_bib0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2042-4280-2-6","article-title":"Cytomegalovirus-induced immunopathology and its clinical consequences","volume":"2","author":"Varani","year":"2011","journal-title":"Herpesviridae"},{"key":"10.1016\/j.jcv.2017.12.011_bib0040","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/ajt.12298","article-title":"CMV infection in the donor and increased kidney graft loss: impact of full HLA-I mismatch and posttransplantation CD8(+) cell reduction","volume":"13","author":"Gatault","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jcv.2017.12.011_bib0045","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.healun.2016.08.014","article-title":"Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors","volume":"36","author":"Forconi","year":"2017","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.jcv.2017.12.011_bib0050","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1128\/JCM.41.8.3757-3764.2003","article-title":"Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay","volume":"41","author":"Hadaya","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2017.12.011_bib0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention, diagnosis and therapy","volume":"13","author":"Kotton","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jcv.2017.12.011_bib0060","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcv.2003.12.010","article-title":"Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients","volume":"30","author":"Piiparinen","year":"2004","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2017.12.011_bib0065","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.biologicals.2016.04.005","article-title":"A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology","volume":"44","author":"Fryer","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.jcv.2017.12.011_bib0070","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000102148","article-title":"Detection and monitoring of cytomegalovirus infection in renal transplant patients by quantitative real-time PCR","volume":"16","author":"Madi","year":"2007","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.jcv.2017.12.011_bib0075","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/ndt\/gfs531","article-title":"Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience","volume":"28","author":"Sund","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jcv.2017.12.011_bib0080","doi-asserted-by":"crossref","first-page":"e5512","DOI":"10.1371\/journal.pone.0005512","article-title":"Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy","volume":"4","author":"Kalil","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2017.12.011_bib0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.jcv.2017.12.011_bib0090","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/TP.0000000000000888","article-title":"Cytomegalovirus infection in pediatric renal transplantation and the impact of chemoprophylaxis with (Val-)ganciclovir","volume":"100","author":"H\u00f6cker","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.jcv.2017.12.011_bib0095","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.bbmt.2011.08.014","article-title":"Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies","volume":"17","author":"Mu\u00f1oz-Cobo","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.jcv.2017.12.011_bib0100","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/ctr.12657","article-title":"Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy","volume":"29","author":"Werzowa","year":"2015","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.jcv.2017.12.011_bib0105","first-page":"CD003774","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","volume":"2","author":"Hodson","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jcv.2017.12.011_bib0110","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1111\/ajt.13486","article-title":"The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation","volume":"15","author":"Martin-Gandul","year":"2015","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jcv.2017.12.011_bib0115","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3129","article-title":"The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation","author":"Reischig","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2017.12.011_bib0120","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1399-0012.2007.00778.x","article-title":"Cytomegalovirus viremia in solid organ transplantation: does the initial viral load correlate with risk factors and outcomes?","volume":"22","author":"Levitsky","year":"2008","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.jcv.2017.12.011_bib0125","doi-asserted-by":"crossref","first-page":"e0163722","DOI":"10.1371\/journal.pone.0163722","article-title":"Randomized controlled trials to define viral load thresholds for cytomegalovirus pre-emptive therapy","volume":"11","author":"Griffiths","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2017.12.011_bib0130","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/tri.12972","article-title":"High human cytomegalovirus DNAemia early post-transplantation associates with irreversible and progressive loss of renal function \u2013 a retrospective study","volume":"30","author":"Lollinga","year":"2017","journal-title":"Transpl. Int."},{"key":"10.1016\/j.jcv.2017.12.011_bib0135","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/QCO.0000000000000173","article-title":"Clinical utility of cytomegalovirus viral load in solid organ transplant recipients","volume":"28","author":"Dioverti","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.jcv.2017.12.011_bib0140","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0140-6736(00)02350-3","article-title":"Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation","volume":"355","author":"Emery","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2017.12.011_bib0145","doi-asserted-by":"crossref","first-page":"e73754","DOI":"10.1371\/journal.pone.0073754","article-title":"Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides","volume":"8","author":"Sakamoto","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2017.12.011_bib0150","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.transproceed.2012.07.144","article-title":"The effects of preemptive therapy using a very low threshold of pp65 antigenemia to prevent cytomegalovirus disease in kidney transplant recipients: a single-center experience","volume":"45","author":"Saracino","year":"2013","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.jcv.2017.12.011_bib0155","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jcv.2004.09.032","article-title":"Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value","volume":"33","author":"Mart\u00edn-D\u00e1vila","year":"2005","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2017.12.011_bib0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.09.017","article-title":"Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection","volume":"56","author":"Mart\u00edn-Gandul","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2017.12.011_bib0165","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1128\/JCM.42.4.1498-1504.2004","article-title":"Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection","volume":"42","author":"Kalpoe","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2017.12.011_bib0170","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/JCM.41.1.187-191.2003","article-title":"Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients","volume":"41","author":"Li","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2017.12.011_bib0175","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/ajt.13791","article-title":"The cell biology of cytomegalovirus: implications for transplantation","volume":"16","author":"Kaminski","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jcv.2017.12.011_bib0180","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.transproceed.2014.11.066","article-title":"Which CMV viral load threshold should be defined as CMV infection in kidney transplant patients?","volume":"47","author":"Eshraghi","year":"2015","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.jcv.2017.12.011_bib0185","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1600-6143.2008.02513.x","article-title":"Interlaboratory comparison of cytomegalovirus viral load assays","volume":"9","author":"Pang","year":"2009","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jcv.2017.12.011_bib0190","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/cid\/cis900","article-title":"An international multicenter performance analysis of cytomegalovirus load tests","volume":"56","author":"Hirsch","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jcv.2017.12.011_bib0195","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/infdis\/jix069","article-title":"Determination of the biological form of human cytomegalovirus DNA in the plasma of solid-organ transplant recipients","volume":"215","author":"Tong","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2017.12.011_bib0200","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/TP.0b013e3181ff8719","article-title":"The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response","volume":"91","author":"Lisboa","year":"2011","journal-title":"Transplantation"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653217303517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653217303517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T21:20:16Z","timestamp":1535145616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653217303517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":40,"alternative-id":["S1386653217303517"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2017.12.011","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2017.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}